Clinical Advancements in the Targeted Therapies against Liver Fibrosis
Hepatic fibrosis, characterized by excessive accumulation of extracellular matrix (ECM) proteins leading to liver dysfunction, is a growing cause of mortality worldwide. Hepatocellular damage owing to liver injury leads to the release of profibrotic factors from infiltrating inflammatory cells that...
Saved in:
| Main Authors: | Ruchi Bansal, Beata Nagórniewicz, Jai Prakash |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | Mediators of Inflammation |
| Online Access: | http://dx.doi.org/10.1155/2016/7629724 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Targeted recombinant fusion proteins of IFNγ and mimetic IFNγ with PDGFβR bicyclic peptide inhibits liver fibrogenesis in vivo.
by: Ruchi Bansal, et al.
Published: (2014-01-01) -
Current strategies for targeted therapy of liver fibrosis
by: D. V. Garbuzenko
Published: (2022-10-01) -
Targeting Fibrosis: From Molecular Mechanisms to Advanced Therapies
by: Xingpeng Di, et al.
Published: (2025-01-01) -
Advancing Chronic Liver Disease Diagnoses: Targeted Proteomics for the Non-Invasive Detection of Fibrosis
by: Andrea Villanueva Raisman, et al.
Published: (2025-01-01) -
Therapeutic approaches for liver fibrosis/cirrhosis by targeting pyroptosis
by: Qiao Guanen, et al.
Published: (2025-07-01)